GU

Question 1

Hereditary syndrome associated with urothelial malignancy and gene

Answer 1

HNPCC - MSH2

Question 2

Treatment of low grade non-muscle invasive bladder cancer

Answer 2

TURBT plus intravesicual mitomycin

Question 3

Treatment of high grade non-muscle invasive bladder cancer

Answer 3

TURBT plus intravescal BCG with maintenance BCG

Question 4

Treatment of stage II/III muscle invasive bladder cancer

Answer 4

neoadjuvant platinum based chemo plus radical cystectomy or chemoradiation

Question 5

Treatment of muscle invasive bladder cancer not amenable to surgery

Answer 5

TURBT + chemoradiation

Question 6

Management of biopsy without muscle present

Answer 6

re-biopsy

Question 7

Treatment of platinum resistant bladder cancer

Answer 7

Atezolizumab

Question 8

Treatment of metastatic bladder cancer

Answer 8

MVAC or Gem/Cis

Question 9

When is staging necessary in prostate cancer

Answer 9

High tumor grade or PSA

Question 10

Risk stratification factors in prostate cancer (3)

Answer 10

Stage
Gleasons
PSA

Question 11

Time for PSA nadir after radiation

Answer 11

1 year

Question 12

Use of degarelix in prostate cancer

Answer 12

Immediate treatment without 1 week of bicalutimide treatment

Question 13

Progression in prostate cancer

Answer 13

Imaging growth or 2 or more new lesions

Question 14

First line treatment of CRPC (2)

Answer 14

abiraterone+pred

enzalutimide

Question 15

Second line treatment of CRPC (2)

Answer 15

either abiraterone or enzalutimide if not tried

docetaxel + prednisone (especially if aggresive)

Question 16

Indication for docetaxel in upfront HSPC

Answer 16

High volume viseral disease

Question 17

More aggressive germ cell hisotology

Answer 17

nonseminoma

Question 18

Tumor marker for nonseminoma

Answer 18

beta-HCG

Question 19

Risk factors for seminoma GCT

Answer 19

extrapulmonary metastasis

Question 20

Risk factors in nonseminoma GCT (2)

Answer 20

extrapulmonary metastasis + elevated serum markers

Question 21

Indications for neoadjuvant chemo in seminoma

Answer 21

Visceral disease

Question 22

Chemo regiemens for testicular cancer (3)

Answer 22

BEP, EP, VIP

Question 23

When to assess tumor markers after orchiectomy

Answer 23

2 weeks

Question 24

Indications for surveillance only after seminoma orchiectomy

Answer 24

Tumor limited to testis and epididymis with N0 or M0

Question 25

Long term monitoring for testicular cancer

Answer 25

CXR, physical exam, and tumor markers

Question 26

Treatment of teratoma

Answer 26

Surgery (chemo resistant)

Question 27

Familial syndrome associated with clear cell RCC

Answer 27

VHL

Question 28

Familial syndrome associated with papillary RCC and gene

Answer 28

Hereditary papillary renal carcinoma | c-MET

Question 29

Size cutoff for nephron sparing surgery

Answer 29

7cm

Question 30

Indications for treatment with IL-2 in RCC

Answer 30

Clear cell, good performance status, younger

Question 31

First line therapy for RCC (2)

Answer 31

sunitinib, pazopanib

Question 32

Second line therapy for RCC (2)

Answer 32

Cabozantinib, axitinib

Question 33

Indications for metastatectomy for metastatic RCC

Answer 33

solitary lesion only

Question 34

Poor risk histologic feature in RCC

Answer 34

sarcomatoid

Question 35

Stauffer syndrome definition

Answer 35

Stauffer syndrome is cytokine-mediated paraneoplastic manifested as nonmetastatic hepatic dysfunction

Question 36

3 vs 4 cycles of BEP in testicular

Answer 36

Good risk - 3 | Intermediate or poor - 4